Investor Presentation Q4 FY 2016 [Company Update]

8/17/2019 Investor Presentation Q4 FY 2016 [Company Update]

1/32


2/32

www.ajantapharma.com

Investor Presentation

Q4 FY 2016

29th April 2016


3/32

2 of 31 F e b r u

a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

Disclaimer

This presentation may include certain ‘forward looking statements’, based on current

expectations, forecasts and assumptions within the meaning of applicable laws and regulations.

They are subject to risks and uncertainties which could cause actual outcomes and results to

differ materially from these statements.

The Company disclaims any obligation to revise any forward-looking statements. The readers

may use their own judgment and are advised to make their own calculations before deciding on

any matter based on the information given herein.

This material is used during oral presentation; it is not a complete record of the discussion.


4/32

3 of 31 F e b r u

a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

Content

India1

Emerging Markets2

Regulated Markets (USA)3

Infrastructure4

Financial Highlights5


5/32

2 9 t h

A p

r i l

2 0 1 6

India


6/32

5 of 31 F e b r u

a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

India Branded Generic Business

Specialty

Segment

Cardiology Ophthalmology

Dermatology

Pain Management

Focused

Marketing

14 Divisions

3,000+ MRs

190+ Products

About 70% products First to Market

Established

Player

Leadership in sub therapeutic segments

Strong Brand Equity

Consistent Innovation

Major chronic portfolio


7/326 of 31

F e b r u

a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

India Sales – Q4 FY 2016

2528

38

6

16

29 30

46

86

Ophthalmology Dermatology Cardiology Pain Mgt. Institution

Q4 FY 2015 Q4 FY 2016

6%

22%

-63%

16%

25%

Revenue Break-up – Q4 FY 2016(Rs. cr.)

Source: Company

97

113

Q4 FY 2015 Q4 FY 2016

Branded Revenue

(Rs. cr.)

114 119

Q4 FY 2015 Q4 FY 2016

Total India

Revenue (Rs. cr.)


8/327 of 31

F e b r u

a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

India Sales – FY 2016

114 118

159

27

62

131121

201

39 35

Ophthalmology Dermatology Cardiology Pain Mgt. Institution

FY 2015 FY 2016

2%

27%

-42%

16%

44%

Revenue Break-up – FY 2016 (Rs. cr.)

Source: Company

480

528

FY 2015 FY 2016

Total India

Revenue (Rs. cr.)

418

492

FY 2015 FY 2016

Branded Revenue(Rs. cr.)


9/328 of 31 F e b r u

a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

Consistent Improvement in Ranking

Source: IMS

5 5 28

13 13 98

20 22 38

Mar 2016 Mar 2015 Mar 2005

Ophthal

Derma

Cardio

Rank

45 53 NAPain

33 36 88Ajanta


10/329 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

14%

18%

14% 14%

12%

23%

11%

29%

25%

27%

Pharma Market Dermatology Cardiology Ophthalmology Pain Mgt.

IPM Ajanta Pharma

Within Segments Ajanta Way Ahead

Mar 2016 - MAT(Source IMS)


11/3210 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p

r i l

2 0 1 6

15%

10% 10%

12%

14%

38%

29%

36%

26%

23%

Mar-2012 Mar-2013 Mar-2014 Mar-2015 Mar-2016

IPM Ajanta Pharma

Faster than Industry - IPM

Source: IMSIPM – Indian Pharmaceutical Market


12/32 2 9 t h

A p r i l

2 0 1 6

Emerging Markets


13/3212 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

Global Presence

Presence in > 30 countries

USA West Asia(3 Countries)

CIS(6 Countries)

South East

Asia(3 Countries)

India

Africa(19 Countries)


14/3213 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

Emerging Markets – Building Brands

Emerging Markets

Customised product portfolio

Front end presence in all markets (650+ MRs)

Gaining market share in existing territories

Asia

344 product registrations

536 product registrations awaiting

approvals

Major segments - Antibiotic, Derma,

Pain, OTC, Ophthal, Cardio, GI

Africa

1,137 product registrations

1,351 product registrations awaiting

approvals

Major segments - Antibiotic, Anti-

Malaria, Multivitamin, Cardio


15/3214 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

EM Revenue Q4 FY 2016 (Consolidated)

133

113

2

174

119

2

Africa Asia Others

Q4 FY 2015 Q4 FY 2016

6%

-30%

31%

Revenue Break-up (Rs. cr.)

248

295

Q4 FY 2015 Q4 FY 2016

Total Revenue (Rs. cr.)


16/3215 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

EM Revenue FY 2016 (Consolidated)

525

426

12

692

461

10

Africa Asia Others

FY 2015 FY 2016

8%

-20%

32%

Revenue Break-up (Rs. cr.)

963

1,163

FY 2015 FY 2016

Total Revenue (Rs. cr.)


17/32 2 9 t h

A p r i l

2 0 1 6

Regulated Markets


18/3217 of 31 F e b r u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

Regulated Markets - USA

Total Approvals - 10

(8 Final Approvals & 2 Tentative approvals)

Under approval – 16

Filing target every year – 8 to 12

ANDA Status 5 Products launched - more in pipeline

Oral Solid - Mix of Para II, III & IV (No FTFs)

Sales & Marketing

2

35

14

Q4 FY

2015 2016

363%

199%

Revenue Q4 FY 2016

(Rs. cr.)


19/32 2 9 t h

A p r i l

2 0 1 6

Infrastructure


20/3219 of 31

F e b r

u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

Manufacturing

API Plant Paithan Plant Dahej Plant

3 existing facilities in Aurangabad, Maharashtra (1 USFDA, UKMHRA, WHO Pre-Q, approved)

1 Facility at Mauritius

Dahej (Gujrat) - undertaking regulatory filing batches

Guwahati (Assam) – Work commenced – Investment Rs. 300 cr.

1 Facility at Waluj (Aurangabad) - Captive Consumption

Formulation Manufacturing

API Manufacturing


21/3220 of 31

F e b r

u a r y

2 0 1 6

2 9 t h

A p r i l

2 0 1 6

R&D

37 37

50

70

106

FY 2012 FY 2013 FY 2014 FY 2015 FY 2016

R&D spend & % of Oper. Income

(Excluding Capex)

4.0% 4.0% 5.0% 6.0%5.0%

Experienced Team of > 650 scientists

Q4 spend (excl. capex) at Rs. 36 cr., FY 2016 at Rs. 106 cr.

FY 2017 expenses expected to be around 7% of Revenue

Capex plan of about Rs. 100 cr. in next 18 months towards

expansion


22/32

2 9 t h A

p r i l

2 0 1 6

Financial Highlights


23/3222 of 31

F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6

P&L – Q4 FY 2016 (Consolidated)

Rs. cr. Q4 FY 2016 % to Sales Q4 FY 2015 % to Sales % Growth

Exports 300 70% 250 67% 20%

Domestic 119 28% 114 31% 5%

Other Op. Income 7 2% 8 2% -23%

Total Revenue 426 372 14%

EBITDA 141 33% 133 36% 6%

PBT 131 31% 115 31% 14%

PAT 106 25% 74 20% 43%


24/3223 of 31

F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6

P&L – FY 2016 (Consolidated)

Rs. cr. FY 2016 % to Sales FY 2015 % to Sales % Growth

Exports 1,178 68% 966 66% 22%

Domestic 528 31% 480 33% 10%

Other Op. Income 23 1% 28 2% -18%

Total Revenue 1,728 1,474 17%

EBITDA 581 34% 505 34% 15%

PBT 547 32% 456 31% 20%

PAT 401 23% 310 21% 30%


25/3224 of 31

F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6

Balance Sheet (Consolidated)

(Rs. cr.)

Equity & Liabilities FY 2016 FY 2015

Shareholders' Funds

Share Capital 18 18

Reserves and Surplus 1,154 823

Sub Total – Shareholders’ Funds 1,172 79% 841 73%

Non-current Liabilities

Long-term borrowings 15 33

Deferred tax liabilities (net) 20 15Other long-term liabilities 0 3

Long-term provisions 3 5

Sub Total – Non-Current Liab. 38 3% 56 5%

Current Liabilities

Short-term borrowings 58 18

Trade payables 146 109

Other current liabilities 57 58Short-term provisions 11 64

Sub Total – Current Liabilities 271 18% 250 22%

TOTAL - LIABILITIES 1,481 1,146


26/32

25 of 31 F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6

Balance Sheet (Consolidated)

(Rs. cr.)

Assets FY 2016 FY 2015

Non-Current Assets

Fixed assets 691 459

Non-current investments - 40

Long-term loans and advances 22 9

Other non-current assets 4 5

Sub-total - Non-current assets 717 48% 513 45%Current Assets

Current Investments 66 19

Inventories 205 44 D 159 40 D

Trade receivables 372 80 D 259 65 D

Cash and cash equivalents 55 137

Short-term loans and advances 65 50

Other current assets 1 9

Sub-total - Current Assets 764 52% 633 55%

TOTAL - ASSETS 1,481 1,146


27/32

26 of 31 F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6

Consistent Track Record (Consolidated)

677

931

1,208

1,446

1,705

2012 2013 2014 2015 2016

(Rs. cr.)

Consolidated Net Sales

77

112

234

310

401

2012 2013 2014 2015 2016

PAT (Rs. cr.) & PAT Margin (%)

11% 12% 19% 21% 23%


28/32

27 of 31 F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6


22%

37%

45%

50%

42%

2012 2013 2014 2015 2016

ROCE(%)

11%12%

19%

21%

23%

2012 2013 2014 2015 2016

Net Margin(%)

29%32%

47%43%

40%

2012 2013 2014 2015 2016

RONW(%)

21%24%

31% 34% 34%

2012 2013 2014 2015 2015

EBITDA Margin(%)


29/32

28 of 31 F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6


913

27

35

46

2012 2013 2014 2015 2016

EPS

(Rs.)

3445

67

96

133

2012 2013 2014 2015 2016

Book Value per share(Rs.)

2

3

4

6

8

2012 2013 2014 2015 2016

Dividend per share(Rs.) (FV Rs. 2/-)

13%15%

18%19% 19%

2012 2013 2014 2015 2016

Dividend Payout(%)


30/32

29 of 31 F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6


0.67

0.32

0.22

0.09 0.08

2012 2013 2014 2015 2016

Total Debt / Equity(Ratio)

77

60 6365

80

2012 2013 2014 2015 2016

Receivable Days(Nos.)

131 134

99

85 82

2012 2013 2014 2015 2016

Payable Days(Nos.)92

5948

4044

2012 2013 2014 2015 2016

Inventory Days(Nos.)


31/32

30 of 31 F e b r

u a r y

2 0 1 6

2 9 t h A

p r i l

2 0 1 6

Awards & Recognitions

"Best Transformational Leader"Award by Asian Centre for Corp. Governance

to

Mr. Yogesh Agrawal

Managing Director (MD)

TIME Magazine“Young Maker of the Year”

award by the hands of

Prime Minister of India

to

Mr. Yogesh Agrawal, MD &

Mr. Rajesh Agrawal, Jt. MD

Mr. Yogesh Agrawal, MD

Listed as"India's Most Valuable CEO"in size companies category by

Business World


32/32

e b r

u a r y

2 0 1 6

h A

p r i l

2 0 1 6

For updates and company information please visit ourwebsite:www.ajantapharma.com

For specific queries, contact:

Rajeev [email protected]

022-66061377

Ajanta Pharma Limited

Ajanta House, Charkop, Kandivli (W), Mumbai 400 067CIN No. - L24230MH1979PLC022059

NSE Symbol : AJANTPHARM ISIN: INE031B01031 BSE Symbol : AJANTAPH Code: 532331

THANK YOU!
mailto:[email protected]:[email protected]

Investor Presentation Q4 FY 2016 [Company Update]

Documents

Transcript of Investor Presentation Q4 FY 2016 [Company Update]